Barrington Strategic Wealth Management Group LLC lowered its position in Abbott Laboratories (NYSE:ABT) by 0.1% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 15,620 shares of the healthcare product maker’s stock after selling 15 shares during the period. Barrington Strategic Wealth Management Group LLC’s holdings in Abbott Laboratories were worth $600,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Fisher Asset Management LLC boosted its position in Abbott Laboratories by 0.4% in the third quarter. Fisher Asset Management LLC now owns 12,435 shares of the healthcare product maker’s stock worth $526,000 after buying an additional 48 shares during the period. City Holding Co. boosted its position in Abbott Laboratories by 0.7% in the third quarter. City Holding Co. now owns 47,279 shares of the healthcare product maker’s stock worth $1,999,000 after buying an additional 314 shares during the period. Searle & CO. bought a new position in Abbott Laboratories during the third quarter worth about $441,000. Ronna Sue Cohen boosted its position in Abbott Laboratories by 1.6% in the third quarter. Ronna Sue Cohen now owns 90,754 shares of the healthcare product maker’s stock worth $3,838,000 after buying an additional 1,460 shares during the period. Finally, Advisory Services Network LLC boosted its position in Abbott Laboratories by 14.8% in the third quarter. Advisory Services Network LLC now owns 5,692 shares of the healthcare product maker’s stock worth $241,000 after buying an additional 735 shares during the period. 62.20% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Shares of Abbott Laboratories (NYSE:ABT) opened at 44.98 on Tuesday. The stock has a market cap of $77.73 billion, a price-to-earnings ratio of 48.00 and a beta of 0.97. Abbott Laboratories has a 1-year low of $36.76 and a 1-year high of $45.84. The firm has a 50-day moving average of $44.15 and a 200 day moving average of $41.25.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Monday, February 6th. The healthcare product maker reported $0.65 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.65. Abbott Laboratories had a net margin of 6.71% and a return on equity of 15.74%. The company had revenue of $5.33 billion for the quarter, compared to analysts’ expectations of $5.41 billion. During the same quarter in the previous year, the company earned $0.62 earnings per share. Abbott Laboratories’s quarterly revenue was up 2.8% on a year-over-year basis. Equities research analysts forecast that Abbott Laboratories will post $2.45 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, May 15th. Investors of record on Friday, April 14th will be given a dividend of $0.265 per share. This represents a $1.06 annualized dividend and a dividend yield of 2.36%. The ex-dividend date is Tuesday, April 11th. Abbott Laboratories’s dividend payout ratio is currently 113.98%.

Your IP Address:

Several brokerages recently weighed in on ABT. TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Wednesday, March 8th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $52.00 price target (up previously from $51.00) on shares of Abbott Laboratories in a research report on Saturday, March 11th. BMO Capital Markets cut shares of Abbott Laboratories from an “outperform” rating to a “market perform” rating and set a $48.00 price target on the stock. in a research report on Tuesday, March 14th. Royal Bank of Canada raised their price target on shares of Abbott Laboratories from $46.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, March 1st. Finally, Zacks Investment Research cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, January 11th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Abbott Laboratories has a consensus rating of “Buy” and an average price target of $48.27.

In related news, insider Heather L. Mason sold 35,700 shares of the business’s stock in a transaction dated Tuesday, January 31st. The shares were sold at an average price of $40.77, for a total transaction of $1,455,489.00. Following the transaction, the insider now owns 100,189 shares in the company, valued at $4,084,705.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Michael J. Warmuth sold 3,851 shares of the business’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $45.39, for a total transaction of $174,796.89. The disclosure for this sale can be found here. Insiders have sold 78,592 shares of company stock worth $3,400,139 in the last quarter. 0.26% of the stock is owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

5 Day Chart for NYSE:ABT

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.